Combination of doxorubicin with TTI-621 (anti-CD47 antibody) has shown anti-tumor effect in animal models, especially in tumors which express high number of CD47 and macrophages, such as leiomyosarcoma (75). This evidence concerns the gene CD47 and leiomyosarcoma.